Table III.
Cox proportional hazards regression analysis for DFS and OS.
| DFS | OS | |||||
|---|---|---|---|---|---|---|
| Parameters | P-value | Relative risk | 95% CI | P-value | Relative risk | 95% CI |
| Age, years (<55 vs. ≥55) | 0.066 | 1.644 | 0.240–3.217 | 0.075 | 1.234 | 0.256–2.768 |
| ER (negative vs. positive) | 0.110 | 0.440 | 0.161–1.205 | 0.210 | 0.330 | 0.330–1.789 |
| PR (negative vs. positive) | 0.059 | 0.324 | 0.101–1.042 | 0.078 | 0.225 | 0.134–1.567 |
| HER2 (0 and 1+ vs. 2+ and 3+) | 0.943 | 1.014 | 0.733–1.403 | 0.956 | 1.002 | 0.567–1.876 |
| ANGPTL4 (negative vs. positive) | 0.011 | 2.353 | 0.733–3.403 | 0.034 | 2.034 | 0.534–3.567 |
| pTNM stage (I+II vs. III+IV) | 0.004 | 2.450 | 1.338–4.488 | 0.002 | 2.678 | 1.448–4.213 |
| Grade (I+II vs. III) | 0.524 | 0.764 | 0.378–2.468 | 0.645 | 0.534 | 1.456–2.145 |
| Tumor size, cm (≤5 vs. >5) | 0.876 | 1.075 | 0.435–2.656 | 0.896 | 0.989 | 0.546–2.132 |
| Lymph node metastasis (no vs. yes) | 0.021 | 1.844 | 1.098–3.099 | 0.043 | 1.234 | 0.987–3.007 |
DFS, disease-free survival; OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ANGPTL4, angiopoietin-like 4.